Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 +/- Bevacizumab in Refractory GTN
NCT02664961Phase 2Terminated
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- Mar 2016
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carotuximab in gestational trophoblastic neoplasia (GTN), sponsored by TRACON Pharmaceuticals, Inc. Primary endpoint: Overall Response Rate on TRC105 Alone and on the Combination of TRC105 and Bevacizumab at 8 weeks. Started Mar 2016; status: terminated.
02
Drugs
carotuximab
03
Conditions
gestational trophoblastic neoplasia (GTN)
Beyond the preview
Go deeper on NCT02664961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02664961.